Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited has announced the issuance of 1,874,964 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This strategic move is part of the company’s efforts to strengthen its financial position, potentially impacting its operational capabilities and market presence.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (IMRN), indicating its international market focus.
Average Trading Volume: 1,014,209
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$19.4M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.